Literature DB >> 15323142

HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.

Barbara G Beatty1, Ronald Bryant, Weichen Wang, Takamaru Ashikaga, Pamela C Gibson, Gladwyn Leiman, Donald L Weaver.   

Abstract

We evaluated HER-2 receptor status by immunocytochemical and immunohistochemical analyses and fluorescence in situ hybridization (FISH) in 51 fine-needle aspiration (FNA) specimens together with the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from surgically resected breast cancers. Three fixation methods were compared: ethanol, formalin, and CytoLyt-ThinPrep (Cytyc, Boxborough, MA). HER-2 was overexpressed and amplified in 8 (16%) of 51 FFPE specimens. Of the 8 cases, gene amplification was observed in 8 FNA specimens (100%) and overexpression in 2 (25%) ethanol-, 4 (50%) CytoLyt-, and 5 (63%) formalin-fixed FNA specimens. Strong pairwise kappa association between FISH results performed on FNA specimens and FFPE tissue samples (ethanol fixation, kappa = 0.848; ThinPrep, kappa = 0.918) and moderate (ThinPrep, kappa = 0.692; formalin fixation, kappa = 0.667) to poor (ethanol, kappa = 0.300) pairwise kappa agreement between tissue immunohistochemical and FNA immunocytochemical results was demonstrated. We conclude that HER-2 protein expression on cytologic preparations was insufficiently reliable for clinical use, whereas HER-2 gene amplification determined by FISH demonstrated strong and consistent correlation with HER-2 status of FFPE tissue samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15323142     DOI: 10.1309/N82C-TQ1J-0XEV-EFQB

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

Review 1.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

2.  Biospecimen reporting for improved study quality (BRISQ).

Authors:  Helen M Moore; Andrea B Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Daniel F Hayes; Pierre Hainaut; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  J Proteome Res       Date:  2011-06-21       Impact factor: 4.466

3.  Biospecimen Reporting for Improved Study Quality.

Authors:  Helen M Moore; Andrea Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Pierre Hainaut; Daniel F Hayes; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  Biopreserv Biobank       Date:  2011-04       Impact factor: 2.300

4.  Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.

Authors:  Claudia Rodriguez; Voichita Suciu; Audrey Poterie; Ludovic Lacroix; Isabelle Miran; Amélie Boichard; Suzette Delaloge; Jacqueline Deneuve; Sandy Azoulay; Marie-Christine Mathieu; Alexander Valent; Stefan Michiels; Monica Arnedos; Philippe Vielh
Journal:  Mol Oncol       Date:  2016-08-05       Impact factor: 6.603

5.  Optical fiber-based in vivo quantification of growth factor receptors.

Authors:  Thommey P Thomas; Yu-Chung Chang; Jing Yong Ye; Alina Kotlyar; Zhengyi Cao; Rameshwer Shukla; Suyang Qin; Theodore B Norris; James R Baker
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 6.  Latest biopsy approach for suspected metastases in patients with breast cancer.

Authors:  Naoki Niikura; Bruno C Odisio; Yutaka Tokuda; Fraser W Symmans; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Nat Rev Clin Oncol       Date:  2013-10-22       Impact factor: 66.675

7.  Her-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry.

Authors:  Kusum Kapila; S Al-Awadhi; Im Francis
Journal:  J Cytol       Date:  2011-04       Impact factor: 1.000

8.  Evaluation of grading and hormone receptor immunostaining on fine needle aspirates in carcinoma breast.

Authors:  Uma Handa; Amit Kumar; Reetu Kundu; Usha Dalal; Harsh Mohan
Journal:  J Cytol       Date:  2015 Jan-Mar       Impact factor: 1.000

9.  Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China.

Authors:  Zhihui Zhang; Peng Yuan; Huiqin Guo; Linlin Zhao; Jianming Ying; Mingrong Wang; Huan Zhao; Qinjing Pan; Binghe Xu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

10.  Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Authors:  Manal F Ismail; Magdy Sayed Aly; Hussein M Khaled; Hanaa M Mohamed
Journal:  Ger Med Sci       Date:  2009-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.